Status:

COMPLETED

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

Lead Sponsor:

University of Florida

Collaborating Sponsors:

Chiesi Farmaceutici S.p.A.

Conditions:

ST Segment Elevation Myocardial Infarction

Percutaneous Coronary Intervention

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

In STEMI patients undergoing PPCI there is a delayed onset of action of oral P2Y12 receptor inhibitors, including prasugrel and ticagrelor. Crushing prasugrel and ticagrelor improves their PK and PD p...

Detailed Description

In STEMI patients undergoing PPCI there is a delayed onset of action of oral P2Y12 receptor inhibitors, including prasugrel and ticagrelor, which require more than 2 hours to exert their full antiplat...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Patients with STEMI undergoing primary PPCI
  • Age \> 18 years old
  • Exclusion criteria:
  • Inability to provide written informed consent
  • Known history of prior intracranial bleeding
  • On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in the prior 10 days
  • Known allergies to aspirin, ticagrelor or cangrelor
  • On treatment with oral anticoagulant
  • Treatment with glycoprotein IIb/IIIa inhibitors
  • Fibrinolytics within 24 hours
  • Active bleeding
  • High risk of bleeding
  • Known platelet count \<80x106/mL
  • Known hemoglobin \<10 g/dL
  • Intubated patients (prior to randomization)
  • Known creatinine clearance \<30 mL/minute or on hemodialysis.
  • Known severe hepatic dysfunction
  • Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection
  • Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.
  • Pregnant or lactating females.

Exclusion

    Key Trial Info

    Start Date :

    November 20 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 13 2018

    Estimated Enrollment :

    50 Patients enrolled

    Trial Details

    Trial ID

    NCT03247738

    Start Date

    November 20 2017

    End Date

    December 13 2018

    Last Update

    September 9 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Florida

    Jacksonville, Florida, United States, 32209